SCHEMBL2072455

SCHEMBL2072455

Cn1c(C2=CC3CCC(C2)N3C(=O)N2CCCc3ccccc32)cc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.42
NOTUM Q6P988 1/20 0.40
CYP11B2 P19099 1/20 0.40
LMNA P02545 2/20 0.39
THRB P10828 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
SMO Q99835 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072451 1.00 HSD11B1 (0.42) HSD11B1NOTUMCYP11B2LMNATHRB
SCHEMBL2071651 0.80 AVPR2 (0.47) HSD11B1NOTUMPOLBSMN1; SMN2TSHR
SCHEMBL2073318 0.80 PDE4B (0.48) HSD11B1NOTUMLMNAPOLBSMN1; SMN2
SCHEMBL2073320 0.80 PDE4B (0.48) HSD11B1NOTUMLMNAPOLBSMN1; SMN2
SCHEMBL2071649 0.80 AVPR2 (0.47) HSD11B1NOTUMPOLBSMN1; SMN2TSHR
SCHEMBL2069944 0.80 HSD11B1 (0.45) HSD11B1NOTUMLMNATHRBPOLB
SCHEMBL2070280 0.80 HSD11B1 (0.45) HSD11B1NOTUMLMNAPOLBSMN1; SMN2
SCHEMBL2070282 0.80 HSD11B1 (0.45) HSD11B1NOTUMLMNAPOLBSMN1; SMN2
SCHEMBL2069941 0.80 HSD11B1 (0.45) HSD11B1NOTUMLMNATHRBPOLB
SCHEMBL2071693 0.79 HSD11B1 (0.43) HSD11B1NOTUMLMNAPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897773-B2 Urea derivatives of tropane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2011-03-01 US disclosed
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-12-23 US disclosed
EP-2046791-B1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-03-24 EP disclosed
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885NOTUM 1364/4885CYP11B2 22/4885
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885NOTUM 1364/4885CYP11B2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.